Indaptus Therapeutics, Inc. (INDP)
Automate Your Wheel Strategy on INDP
With Tiblio's Option Bot, you can configure your own wheel strategy including INDP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INDP
- Rev/Share 0.0
- Book/Share 0.1985
- PB 2.0148
- Debt/Equity 0.0213
- CurrentRatio 1.8994
- ROIC -5.5942
- MktCap 6413760.0
- FreeCF/Share -0.9526
- PFCF -0.4774
- PE -0.3582
- Debt/Assets 0.011
- DivYield 0
- ROE -3.3304
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, announces that its chief medical officer, Roger Waltzman, M.D., M.B.A. will be moderating a panel at the annual CMO360 Summit, being held April 7-8 in Boston.
Read More
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of Decoy20. As announced in last week's earnings release, the Company has now enrolled more than 20 patients in the weekly dosing cohort, marking a key milestone in the trial.
Read More
Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that Michael Newman, Founder and Chief Scientific Officer, will present at the 10th Annual Innate Killer Summit, taking place from March 3-5, 2025, in San Diego, California. Dr. Newman will deliver a scientific presentation on Tuesday, March 4, 2025, titled, “Employing Attenuated & Killed Gram-Negative Bacteria to Induce NK-Mediated Anti-Tumor Immunity.
Read More
About Indaptus Therapeutics, Inc. (INDP)
- IPO Date 2015-08-04
- Website https://indaptusrx.com
- Industry Biotechnology
- CEO Mr. Jeffrey A. Meckler J.D.
- Employees 7